The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I am heartbroken at people losing loved ones and business being crippled.
One thing the British are excellent at, is invention and innovation.
Although our investment is at risk, it's great that Sng have a good shot at making a difference.
Sadly I don't think the ruby slippers are going to work on this one. Flare-ups are inevitable. Sadly our government thinks rushing to open air corridors and our deserving UK population off to Benidorm comes above rational restraint and we will pay for that. Pubs are too soon as 'we' are not responsible enough in the UK. If as we hope, most cases can be shifted to the mild spectrum by early palliative intervention, then it will of course be a huge step.
I am deeply concerned. A second wave in the Uk would put pressure on our social and economic well being, as it will on the rest of the World
I wish coronavirus would go away.
Catalonia Spain, has come up on the radar. I believe it's worth keeping an eye on Italian and Spanish news as an indication of what's likely to happen in UK.
The article regarding 3rd way of contagion regarding the concern of 200 scientists is by Richard Read. Los Angeles Times
There is a 3rd way of infection that has raised concern with 200 scientists across the globe.
According of research, tiny particles of coronavirus can remain several feet in the air for a considerable amount of time.
Scara, my sentiments exactly.
Nolupus, hit the nail on the head with a recent post. Its crucial we only invest what we can truly afford to lose.
Most definalty, but with some people showing no signs of symptoms, and some people having mild symptoms, if sng001 can give a little boost to people before the need to go to hospital then that in it self maybe a major benefit to the NHS in this country and also around the world.
Shrubs not scrubs. Auto correct is irritating.
Profound my theory appears. I believe the human being is nothing more than an organic mass. Darwin considered the same opinion in a round about sort of way.
Different plants, scrubs and trees react differently according to conditions of environment.
Forna and flora responds differently to plant
food,chemical or organic care.
I suggest our treatment sgn001 will work on some people but not all, as we are all genetically different.
Yes agree with the ace 2 receptor. The virus getting into the system is through the mouth, nose, lungs, eyes. Inhaled interferon should hopefully deal with 3 out of the 4. And boost the immune system. So much more to understand about this virus.
Dosing through IV means that all organs will get their share of ifn B , and not just the lungs ....flip side ..the higher the dose , the more risk of side effects ...
What is really the most intriguing is the fact that nearly 50% of MS patients don't respond to ifn beta ....
We come back once again to the thesis of fine tuning the immune system in relation to onés interferon signature , imo
Fantastic article and highlights the benefits of interferon beta, I would imagine the IV route solely in hospital treatment. With a higher dose possibly having more side effects? A targeted dose direct to the lungs potentially more beneficially? Or Nolupus if the dose isn't enough for the other benefits?
I peeped at the Faron Board they are worried about the trial stopping I guess they are waiting on news to se whats happeing.
now the whole*
I guess they would be one of our main competitors in a phase three trial. not the who thing about it reducing cytokine stormes makes me less happy
Dosing levels and not doing levels grrr
Greenfish89,
Both molecules are the same , ifn beta 1a
But they differ in the doing levels as well as administration methods
Farn is IV administrated
SNG001 is an inhaled formula
Is ifn B1a diffrent from our ifn b1? I read there rns saying they are upping production and the artical was all about how iv injections were much better than sc injections. I get how they are likely to to shout about inf b1 from the roof tops so it might not be 100% reliable. They got 2.1 million euros to bump up production from the EU
I should point out that the authors are all directly associated with Faron .....
Severely ill COVID-19 patients with increased levels of plasma cytokines (especially IL-6) show signs of immune exhaustion and poor IFN responses [13]. Even in such cases, these patients would most likely benefit from IFN-beta, because it is the most potent anti-viral and anti-inflammatory agent of all interferons. It can induce the desired immune boost, but simultaneously downregulate IL-6 and IL-8 [14] and impair extravasation of neutrophils into lungs [15].
Conclusions
IFN-beta is now among the leading candidates to treat COVID-19 in various clinical trials, and i.v. and s.c. routes of administration are considered to be equal. This is not the case due to the different bioavailabilities of IFN-beta via i.v. and s.c. injections in target organs. This aspect needs to be taken seriously, when critically ill patients with compromised peripheral circulation are treated.
I like these end bits
Cracking info there, some of the language is difficult to digest. I have cut the first paragraph which I believe is important for treatment for covid 19. Not just the initial viral load, but the reduced vascular leakage, (Ards) and also the adenosine upreguate of cd73 anti imflammatory response, would this reduce the cytokine storm.
Type I interferons (interferon alpha and beta among others) are our first line of defence in infections (Levy et. al., 2003). As a counter measure to acute insults type I interferons enhance cell membrane and vascular integrity. Vascular leakage is an important feature in sepsis; severe respiratory viral infections, such as MERS, SARS and influenza; viral hemorrhagic fever, such as Ebola; systemic inflammatory response syndrome (SIRS) and ischemia-reperfusion injuries brought forth by major trauma or cardiovascular surgery. Type I interferons have the ability to up-regulate CD73, a molecule which yields anti-inflammatory adenosine (Jalkanen and Salmi, 2006). CD73 derived adenosine enhances endothelial barrier function and leads to the prevention of vascular leakage, the predominant pathophysiological event in acute organ injury (Kiss et. al., 2007), namely acute respiratory distress syndrome (ARDS), acute kidney injury (AKI) and multi-organ failure (MOF). Vascular leakage in acute lung injury (ARDS) allows plasma exudation into the alveolar space leading to potentially life-threatening hypoxaemia. Interferon beta-1a has been shown to reduce the impact of ARDS by reducing vascular leakage (Bellingan et. al., 2014).
My conclusion is that given at the right time this treatment could be a game changer. Which treats the majority of the c19 symptoms from early onset to when the infection leads to the point of going onto a ventilator. (Ards, cytokine storm late stage covid 19) all IMO of which I will be happily corrected. DYOR.
https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03048-5
Picked up on the farn board
https://patents.justia.com/patent/20200199677
Some good info